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1. Introduction 
Myocardial protection with cardioplegia has resulted in significant improvement in the 
outcomes of cardiopulmonary bypass (CPB) in coronary artery - bypass graft (CABG) 
procedure. However, subendocardial damage created by ischemic injury still remains a source 
of morbidity and mortality associated with CABG (1). Ventricular fibrillation (VF) occurring 
after releasing of aortic cross-clamp in the reperfusion phase of CABG surgery (reperfusion 
VF) is very common (74–96 %) (1-5). This complication is considered to be related with 
ischemia-induced increases in reentry and automaticity as well as the possibility of reperfusion 
injury (6-8). Reperfusion VF may adversely affect coronary blood flow and increase ventricular 
wall tension, which causes a further depletion of myocardial energy reserves in an energy-
depleted myocardium (2). It is estimated that reperfusion VF occurs as a result of increased 
myocardial wall stress and oxygen consumption besides diminished subendocardial blood 
flow and intramyocardial acidosis (9-12). Additional myocardial injury following defibrillation 
by direct current countershocks may worsen this situation (13,14). Therefore, it would be 
helpful for the patients’ recovery after the CABG (15). 
VF developing in reperfusion phase of CPB generally responds to defibrillation. Obstinate 
or recurrent VF increases myocardial oxygen demand, unfortunately resulting in ventricular 
dilatation. Furthermore, the ventricular relaxation creates irreversible myocardial injury. 
When heart remains in VF, it is necessary to recheck blood gases, electrolytes, and 
temperature. Lidocaine, a class Ib antiarrhythmic, is administered at a dose of 1 to 2 mg kg-1 
before repeated direct current defibrillation is attempted. Occasionally, beta blockers such as 
esmolol and metoprolol, class II antiarrhythmics and amiodarone, a class III antiarrhythmic 
are added in order to treat intractable VF or ventricular tachycardia (16). A previous study 
reported that in patients with persistent VF during weaning from CPB in cardiac surgery for 
heart diseases with left ventricular hypertrophy, amiodarone was a reasonable option (17).  
Lidocaine, which is a local anaesthetic in amid group, acts as an antiarrythmyhic agent and 
it is classified in class Ib. By binding Na+ channels, lidocaine alters membranous conductivity 
                                                 






of cations. Lidocaine decreases depolarisation plateau of phase 4 and enhances diastolic 
electrical flow threshold in Purkinje fibers (18,19). Lidocaine increases VF threshold, but this 
effect is directly related with plasma concentrations of lidocaine (20). 
Although lidocaine is known to reduce VF incidence and defibrillation demand, the 
mechanism is not clearly understood yet. However, it is proved to be appropriate in the 
treatment of ventricular ectopic premature beats (18-21). In myocardial ischemic conditions, 
lidocaine has been shown to turn unidirectional blocking zones and slow conduction in 
ischemic zones to complete blocking areas (22). Another possible mechanism could be 
explained by inhibitory effect of lidocaine on Na+ intake and membrane depolarisation such 
that cardiac arrest occurs when they are inhibited (23). As a result, the energy is kept away 
from electromechanical activity thus proceeding more accurate recovery for the heart. In 
addition to that local anaesthetics, lidocaine can block slow Ca++ channels and Ca++ channels 
of sarcoplasmic reticulum (24,25). 
Lidocaine has previously been added to cardioplegic solutions in order to prevent 
reperfusion VF (see table 1). When 500 mg L-1 of lidocaine was added to a crystalloid 
solution, there was a significant decrease in the incidence of VF, but a higher percentage 
of atrio-ventricular (AV) block was also observed (4-12,14,26). Baraka et al. (13) showed 
that the incidence of reperfusion VF can be markedly reduced, from 93% to 42%, with the 
addition of 100 mg L-1 of lidocaine to a crystalloid cardioplegic solution without an 
increase of the incidence of AV block. Wallace and Baker (2) repeated a similar study and 
reported that the incidence of reperfusion VF is reduced from 63 % to 42 % with the 
addition of 100 mg L-1 of lidocaine to a crystalloid cardioplegic solution. They noted that a 
higher proportion of the patients who developed reperfusion VF with lidocaine 
cardioplegia underwent spontaneous defibrillation (30% versus 11%), even though this 
was not statistically significant. On the other hand, different from the above mentioned 
study (13), they stated that the incidence of AV block necessitating ventricular pacing to 
separate from CPB was significantly higher in the lidocaine treated group (44%) as 
compared with the control group (20%). Sellevold et al. (27) added procaine instead of 
lidocaine in cardioplegic solutions to be able to observe the efficiency in post-ischemic 
rhythm disturbances, and they showed that cardioplegia with procaine (1 mM) stabilised 
post-ischemic arrhythmia without any reverse effect. 
Meta-analyses suggested that prophylactic lidocaine use reduces VF but increases mortality 
rates after acute myocardial infarction. Although its use may not be associated with 
increased mortality rates, the prophylactic lidocaine use, in fact, has decreased with the 
advent of thrombolysis, and the routine use of prophylactic lidocaine in acute myocardial 
infarction is not recommended (28,29). In another study, lidocaine appears to be effective in 
converting no more than 20% of stable ventricular tachycardias (30).  
In some investigations, the possible effect of lidocaine on autonomic cardiac control in humans 
was studied. Aidonidis et al. (31) found that in anaesthetized dogs, there was marked 
attenuation of cardiac sympathetic nervous activity by lidocaine which slightly altered efferent 
cardiac sympathetic nervous activity in the course of acute myocardial ischemia and 
reperfusion, but significantly increased it during VF. Abramovich et al. (32) showed that 
lidocaine has a consistent and significant parasympatholytic effect on the human heart in 
healthy volunteers as well as in patients in the acute phase of myocardial infarction. 
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Authors Lidocaine Doses Results 
Hottenrott C et al, 1974 (9)   
Dahl CF et al, 1974 (14)   
Buckberg GD and Hottenrott 
CE, 1975 (10) 
  
Hearse DJ, 1977 (8)   
Murdock D et al, 1980 (6) 
500 mg L-1  
(in the cardioplegic solution)
Decreasing in the incidence 
of VF with higher percentage 
of AV block than the control 
group 
Kaplinsky E et al, 1981 (7)   
Tchervenkov CI et al, 1983 (4)   
Tchervenkov CI et al, 1983 
(26) 
  
Khuri SF et al, 1985 (11)   
Lockermen ZS et al, 1987 (12)   
Fiore AC et al, 1990 (5)   
Baraka A et al, 1993 (13) 
100 mg L-1 
(in the cardioplegic solution)
Decreasing in the incidence 
of VF without any increasing 
the incidence of AV block 
group 
Wallace SR and Baker AB, 
1994 (2) 
100 mg L-1 
(in the cardioplegic solution)
Decreasing in the incidence 
of VF without any increasing 
the incidence of AV block 
Praeger IP et al,1988 (41) 
200 mg in bolus 
(before aortic declamping) 
Decreasing in the incidence 
of VF  
Kirlangitis J et al, 1990 (40) 
2 mg kg-1 in bolus 
(before aortic declamping) 
Decreasing in the incidence 
of VF 
Landow L et al, 1990 (42) 
1.5 mg kg-1 in bolus with 
2 mg min-1 infusion rate 
(before aortic declamping) 
No malign dysrhythmia 
Juneja R et al, 1993 (43) 
1.5 mg kg-1 in bolus with 
2 mg min-1 infusion rate 
(before aortic declamping) 
Nondecreasing in the 
incidence of VF in patients 
with poor left ventricular 
function 
Rinnie T and Kaukinen S, 
1998 (44) 
Continuous infusion for 20 
hours with a bolus dose 
(before aortic clamping) 
Nondecreasing in the 
incidence of VF 
Baraka A et al, 2000 (15) 
100 mg in bolus 
(before aortic declamping) 
Decreasing in the incidence 
of VF with higher percentage 
of AV block than the control 
Table 1. The results of the studies about lidocaine use to reperfusion VF 
Despite the theoretical advantages of lidocaine for the treatment of VF in the 
cardiopulmonary resusitation, it is well recognized that lidocaine can increase defibrillation 






majority of cases of VF because of not only its potential to increase the defibrillation 
threshold, but also its negative inotropic activity. Its use is probably best reserved for cases 
of persistently recurring VF after electrical defibrillation, particularly in association with 
reperfusion occurring after heart surgery (34,37,38). 
Hottenrott et al. (9) showed the augmentation of coronary blood flow to a sufficient rate 
towards increased energy demand in normal heart and in normothermic condition. They 
reported that redistribution occurs to keep endocardial / epicardial blood flow proportion. 
However, in hypertrophied and distended hearts and if a low aortic perfusion pressure 
exists, coronary blood flow will not be enough to meet increased oxygen consumption and 
this aspect can be explained by showing diminished coronary sinus pH, increased lactate 
levels and K+ concentrations. In patients with severe coronary artery stenosis, the occurrence 
of VFs aggravates subendocardial ischemic injury in detoriated left ventricle. 
Khuri et al. (11) reported the adverse effect of VF despite venting of heart and hypothermic 
conditions in reperfusion state of CPB, using continuous intraoperative intramyocardial pH 
monitoring technique.  
Dahl et al. (14) demonstrated myocardial necrosis due to defibrillation in dogs and they 
proved the relation between the width of pedals and the frequency of defibrillation on 
myocardial injury. If the pedals are small or the frequency is scarce between defibrillations, 
the intensity of injury will be greater. 
Manolis et al. (39) compared the efficiency and safety of lidocaine and tocainide given 
intravenously in patients with arrhythmia following cardiac surgery. They found that the 
drugs were both efficient, and there was not any statistical difference between these two 
drugs. In their study, they had administered 100 mg lidocaine in bolus before 60 mg 
infusion for 15 minutes. The infusion had been continued in a dose of 1.4 mg min-1 and the 
blood level had been found to be 1-4 mg L-1. 
Kirlangitis et al. (40) compared the efficacy of bretylium (10 mg kg-1), lidocaine (2 mg kg-1) 
and (as placebo) saline to prevent or to reduce VF incidence during reperfusion phase after 
aorta declamping. VF was seen 91% with saline, 64% with lidocaine and 36% with 
bretylium. The need for defibrillation was found lower with lidocaine and bretylium than 
saline group, but among two drugs they did not find any significant differences. 
Praeger et al. (41) showed that the incidence of VF was reduced to less than 33% with 
treatment with 200 mg of lidocaine intravenously 3 minutes before aortic declamping. In 
patients who had serum potassium levels that were higher than 5.1 mEq/l and treated with 
lidocaine before aortic delamping, the incidence of VF decreased to less than 15%. 
Landow et al. (42) administered 1.5 mg kg-1 lidocaine in bolus with 2 mg min-1 infusion rate 
before aorta declamping. In more than 50% of the patients, lidocaine serum levels were 
found to be in sub-therapeutic borders, but free lidocaine levels were within therapeutic 
limits. During this study, they didn’t realise any malign dysrhythmia. Following this study, 
Juneja et al. (43) performed another study using similar lidocaine doses and reported that in 
patients with poor left ventricular function, prophylactic lidocaine did not reduce 
ventricular arrhythmias after CABG surgeries.  
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Rinne and Kaukinen (44) studied the effect of an intravenous bolus of lidocaine given before 
clamping the aorta, which was followed by a continuous infusion for as long as 20 hours. 
They did not observe any increase in cardiac protection as evidenced by the analysis of 
serum troponin concentration and serum creatine kinase MB activity and by the 
electrocardiogram. They did not report any decrease in the incidence of reperfusion VF.  
Baraka et al. (15) showed that the incidence of reperfusion VF could be significantly 
decreased without any increase in the incidence of AV block with the administration of a 
bolus of 100 mg of lidocaine by way of the pump 2 minutes before the release of the aortic 
cross-clamp. In this study, the better cardiac output after weaning from CPB in the lidocaine 
group versus the control group was noted. They suggested that the result might be 
explained by the significant decrease of reperfusion VF in the lidocaine group (11 % versus 
70 %). 
2. Conclusion 
We concluded that following the CABG surgery, the incidence of reperfusion VF is quite 
high. During the CABG surgery, as a prophylactic measure, the administration of lidocaine 
at a dose of 1 to 2 mg kg-1 before releasing the aortic cross-clamp can decrease the incidence 
of reperfusion VF. However, because of the risk of AV block with using lidocaine, we 
believe that in patients with persistent VF and also with left venricular hypertrophy or 
dysfunction, the use of other anti-arrhythmic drugs would be more helpful for defibrillation. 
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